share_log

三葉草生物-B：董事會會議日期

CLOVER BIO-B: DATE OF BOARD MEETING

香港交易所 ·  Mar 14 04:33
Summary by Moomoo AI
三葉草生物製藥有限公司（「三叶草生物-B」）將於2024年3月26日（星期二）召開董事會會議，主要議程為考慮及批准截至2023年12月31日止年度的全年業績報告及其發佈。會議同時將評估是否派付末期股息。董事會成員包括執行董事梁朋博士及梁果先生，非執行董事王曉東博士、Donna Marie AMBROSINO博士、Ralf Leo CLEMENS博士，以及獨立非執行董事吳曉濱博士、廖想先生、Jeffrey FARROW先生和Thomas LEGGETT先生。
三葉草生物製藥有限公司（「三叶草生物-B」）將於2024年3月26日（星期二）召開董事會會議，主要議程為考慮及批准截至2023年12月31日止年度的全年業績報告及其發佈。會議同時將評估是否派付末期股息。董事會成員包括執行董事梁朋博士及梁果先生，非執行董事王曉東博士、Donna Marie AMBROSINO博士、Ralf Leo CLEMENS博士，以及獨立非執行董事吳曉濱博士、廖想先生、Jeffrey FARROW先生和Thomas LEGGETT先生。
CLOVER BIOPHARMACEUTICAL CO., LTD. (“CLOVER BIO-B”) WILL HOLD A BOARD MEETING ON TUESDAY, MARCH 26, 2024. THE MAIN AGENDA IS TO CONSIDER AND APPROVE THE ANNUAL RESULTS REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 AND ITS PUBLICATION. The meeting will also assess whether a final dividend will be paid. The members of the Board of Directors include Executive Directors Dr. Leung Pang and Mr. Liang Guo, Non-Executive Directors Dr. Wang Xiaodong, Dr. Donna Marie AMBROSINO, Dr. Ralf Leo CLEMENS, and Independent Non-Executive Directors Dr. Wu Xiaobin, Mr. Liao Chou, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT.
CLOVER BIOPHARMACEUTICAL CO., LTD. (“CLOVER BIO-B”) WILL HOLD A BOARD MEETING ON TUESDAY, MARCH 26, 2024. THE MAIN AGENDA IS TO CONSIDER AND APPROVE THE ANNUAL RESULTS REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 AND ITS PUBLICATION. The meeting will also assess whether a final dividend will be paid. The members of the Board of Directors include Executive Directors Dr. Leung Pang and Mr. Liang Guo, Non-Executive Directors Dr. Wang Xiaodong, Dr. Donna Marie AMBROSINO, Dr. Ralf Leo CLEMENS, and Independent Non-Executive Directors Dr. Wu Xiaobin, Mr. Liao Chou, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more